N.V. Organon

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

This source was last successfully updated at 2026/11/10 18:31; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Accepted: 16 applicationsNo longer listed under review: 2 applications

1. 2026/10/31No longer listed under review

   No verified English name

   JYHB2500642

   Fact date: 2026/10/31 · Site observation date: 2026/10/31

   Accepted: 2025/11/27

   not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked

   View source ↗
2. 2026/10/31No longer listed under review

   No verified English name

   JYHB2500641

   Fact date: 2026/10/31 · Site observation date: 2026/10/31

   Accepted: 2025/11/27

   not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked

   View source ↗
3. 2026/10/10Accepted

   Etoricoxib Tablets

   JYHZ2600262

   Fact date: 2026/10/10 · Site observation date: 2026/10/22

   View source ↗
4. 2026/10/10Accepted

   Etoricoxib Tablets

   JYHZ2600261

   Fact date: 2026/10/10 · Site observation date: 2026/10/22

   View source ↗
5. 2026/10/10Accepted

   Etoricoxib Tablets

   JYHZ2600260

   Fact date: 2026/10/10 · Site observation date: 2026/10/22

   View source ↗
6. 2026/10/10Accepted

   Etoricoxib Tablets

   JYHZ2600259

   Fact date: 2026/10/10 · Site observation date: 2026/10/22

   View source ↗
7. 2026/10/10Accepted

   Etoricoxib Tablets

   JYHZ2600258

   Fact date: 2026/10/10 · Site observation date: 2026/10/22

   View source ↗
8. 2026/10/10Accepted

   Etoricoxib Tablets

   JYHZ2600257

   Fact date: 2026/10/10 · Site observation date: 2026/10/22

   View source ↗
9. 2026/10/10Accepted

   Etoricoxib Tablets

   JYHZ2600256

   Fact date: 2026/10/10 · Site observation date: 2026/10/22

   View source ↗
10. 2026/10/10Accepted

    Etoricoxib Tablets

    JYHZ2600255

    Fact date: 2026/10/10 · Site observation date: 2026/10/22

    View source ↗
11. 2026/09/21Accepted

    Simvastatin Tablets

    JYHZ2600230

    Fact date: 2026/09/21 · Site observation date: 2026/10/22

    View source ↗
12. 2026/09/21Accepted

    Simvastatin Tablets

    JYHZ2600229

    Fact date: 2026/09/21 · Site observation date: 2026/10/22

    View source ↗
13. 2026/09/16Accepted

    Ganirelix Injection

    JYHB2600523

    Fact date: 2026/09/16 · Site observation date: 2026/10/22

    View source ↗
14. 2026/09/16Accepted

    Ezetimibe and Simvastatin Tablets

    JYHB2600521

    Fact date: 2026/09/16 · Site observation date: 2026/10/22

    View source ↗
15. 2026/09/16Accepted

    Ezetimibe and Simvastatin Tablets

    JYHB2600520

    Fact date: 2026/09/16 · Site observation date: 2026/10/22

    View source ↗
16. 2026/09/10Accepted

    No verified English name

    JTS2600142

    Fact date: 2026/09/10 · Site observation date: 2026/10/22

    View source ↗
17. 2026/08/27Accepted

    No verified English name

    JYHB2600494

    Fact date: 2026/08/27 · Site observation date: 2026/10/22

    View source ↗
18. 2026/08/27Accepted

    No verified English name

    JYHB2600493

    Fact date: 2026/08/27 · Site observation date: 2026/10/22

    View source ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

CDE acceptances and review

Last successful update: 2026/11/11 06:42

Chemical-drug catalogue

Last successful update: 2026/11/11 06:38

Full API register

Last successful update: 2026/11/11 06:40

NMPA drug delivery notices

Last successful update: 2026/11/10 18:31 · Current coverage may be incomplete

First index-page publication dates: — to —; 0 pages pending. Covers loaded notices only, not a complete historical approval database.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Drug names use verified official English names only. Missing names are shown as No verified English name, linking to a Chinese page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized. Original statutory reference numbers are the sole visible Chinese exception.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Chinese free text is not displayed; use the source links or source-name columns in CSV exports.

Public drug landscapes ↗